Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC74472 Conatumumab

    AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody

    Conatumumab(AMG 655)是针对人死亡受体5(DR5,TRAILR2)的人单克隆激动剂抗体(Kd:1nM的长形式DR5,0.8nM的短形式DR5)。
  3. GC74469 Tabalumab

    他贝芦单抗; LY2127399

    Tabalumab (LY2127399)是一种人抗BAFF (b细胞活化因子)单克隆抗体(IgG4型),具有中和膜结合和可溶性BAFF的活性。
  4. GC74467 Cemiplimab

    西米普利单抗

    Cemiplimab(抗人PD-1)是一种高亲和力程序性死亡受体-1(PD-1)单克隆IgG4抗体,可阻断PD-1/PD-L1介导的T细胞抑制。
  5. GC74464 Cadonilimab

    卡度尼利单抗; AK104

    Cadonilimab(AK104)是一种靶向PD1/CTLA4的人源化四价IgG1双特异性抗体。
  6. GC74462 Zimberelimab

    赛帕利单抗; GLS-010; AB-122; WBP-3055

    Zimberelimab(GLS-010)是一种完全人IgG4抗PD-1单克隆抗体,对人PD-1的EC50为210pM。
  7. GC74460 Visugromab

    CTL-002

    Visugromab (CTL-002)是一种GDF-15中和IgG4单抗。
  8. GC74449 Vonsetamig Vonsetamig是一种人源免疫球蛋白G4-kappa,抗tnfrsf17和CD3E单克隆抗体。
  9. GC74441 Evunzekibart

    ATOR-1017

    Evunzekibart (tor -1017)是一种Fc-γ受体条件4-1BB激动剂和igg4型抗体。
  10. GC74430 Exlinkibart

    LVGN-6051

    Exlinkibart(LVGN-6051)靶向TNFRSF9,是一种通过互补决定区(CDR)移植技术人源化的IgG1κ抗体。
  11. GC74424 Boserolimab

    MK-5890

    Boserolimab(MK-5890)是一种人源化激动剂单克隆抗体,与CD27结合提供共刺激信号,增强T细胞介导的反应。
  12. GC74422 Duvakitug Duvakitug是一种人源IgG1-λ2单克隆抗体,靶向TNFSF15/TL1A。
  13. GC74380 Ac-VRPR-AMC TFA Ac-VRPR-AMC TFA是一种荧光的metacaspase底物。
  14. GC74358 PNC-27 acetate PNC-27 acetate是一种嵌合p53-穿透素肽,以p53肽样结构与HDM-2结合,诱导选择性膜孔形成并导致癌细胞裂解。
  15. GC74313 MYBMIM MYBMIM是MYB:CBP/P300复合物分子组装的抑制剂。
  16. GC74305 CD24/Siglec-10 blocking peptide, CSBP CD24/Siglec-10 blocking peptide, CSBP不仅可以阻断CD24/ siglece -10的相互作用,还可以阻断PD-1/PD-L1的相互作用。
  17. GC74270 Penduletin Penduletin是一种黄酮类化合物,可以从白蜡和牡荆中分离出来。
  18. GC74267 Propylparaben-d4

    尼泊金丙酯-d4; Propyl parahydroxybenzoate-d4; Propyl 4-hydroxybenzoate-d4

    Propylparaben-d4是氘标记的尼泊金丙酯。
  19. GC74256 Condurango glycoside A Condurango glycoside A是p53的激活剂。
  20. GC74252 Euphornin Euphornin是一种抗癌剂,可从E. helioscopia中分离得到。
  21. GC74187 Salicylic acid-13C6

    2-Hydroxybenzoic acid-13C6

    Salicylic acid-13C6是13c标记的水杨酸。
  22. GC74159 MK-0731 MK-0731是一种选择性、非竞争性和变构驱动蛋白纺锤体蛋白(KSP)抑制剂,IC50为2.2 nM,pKa为7.6。
  23. GC74102 Apomine

    SR-45023A; SR 9223i; SK&F-99085

    Apomine (SR-45023A)是一种抑制胆固醇合成中甲羟戊酸/类异戊二烯途径的抗肿瘤药物。
  24. GC74090 Dimethyl fumarate-d2

    富马酸二甲酯-d2

    Dimethyl fumarate-d2是氘标记的富马酸二甲酯。
  25. GC74080 TASIN-30 TASIN-30是一种EBP抑制剂,EBP竞争的EC50值为0.097 μM, DHCR7竞争的EC50值为50 μM。
  26. GC74075 SC428 SC428是一种靶向N-末端结构域的雄激素受体(AR)抑制剂。
  27. GC74070 INF 195 INF 195是一种NLRP3抑制剂。
  28. GC74050 PROTAC CDK4/6 degrader 1 PROTAC CDK4/6 degrader 1(化合物7f)是CDK4和CDK6的双重降解剂,DC50分别为10.5和2.5 nM。
  29. GC74047 UR778Br UR778Br靶向IQGAP1蛋白的GTP酶激活蛋白相关结构域(GRD结构域)。
  30. GC74043 Bfl-1-IN-2 Bfl-1-IN-2(化合物13)是Bfl-1的可逆共价抑制剂(IC50:4.3μM)。
  31. GC74042 SpiD3 SpiD3是一种新型的螺环二聚体。
  32. GC74030 ASCT2-IN-2 ASCT2-IN-2(化合物25e)是一种ASCT2抑制剂,IC50为5.14μM。
  33. GC74029 ASCT2-IN-1 ASCT2-IN-1(化合物20k)是一种ASCT2抑制剂,在A549和HEK293细胞中的IC50值分别为5.6 μM和3.5 μM。
  34. GC74024 BPU BPU在亚g1期阻止细胞周期进程。
  35. GC74007 SelSA SelSA是一种选择性的口服活性组蛋白去乙酰化酶6 (HDAC6)抑制剂,IC50为56.9 nM。
  36. GC74001 TS-24 TS-24是组织蛋白酶S的抑制剂,IC50为4.3μM。
  37. GC73996 PROTAC AR/AR-V7 degrader-1 PROTAC AR/AR-V7 degrader-1(27c)是一种基于PROTAC的双AR AR-V7降解器,AR和AR-V7的DC50值分别为2.67和2.64μM。
  38. GC73995 XL44 XL44是一种hRpn13结合物,可诱导hRpn13依赖性细胞凋亡,并通过pclaf依赖性机制限制细胞活力。
  39. GC73990 SDU-071 SDU-071是BRD4-p53抑制剂的强效口服活性抑制剂。
  40. GC73986 MX106-4C MX106-4C是一种选择性杀死abcb1阳性结直肠癌细胞的survivin抑制剂。
  41. GC73982 NSD-IN-3 NSD-IN-3(化合物3)是一种强效的核受体结合SET结构域(NSD)抑制剂。
  42. GC73980 GGTI-2417 GGTI-2417是GGTase I的强效选择性抑制剂。
  43. GC73973 MY-1442 MY-1442(I-3)是微管蛋白聚合抑制剂。
  44. GC73950 SC912 SC912是AR-V7抑制剂(IC50 = 0.36 μM)。
  45. GC73943 Polθ/PARP-IN-1 Polθ/PARP-IN-1(化合物25d)是一种有效的双DNA聚合酶θ (Polθ)和PARP抑制剂,IC50值分别为45.6和5.4 nM。
  46. GC73940 BFC1108 BFC1108是一种小分子Bcl-2功能转换器。
  47. GC73939 ATPase-IN-3 ATPase-IN-3(化合物6)是一种atp酶抑制剂。
  48. GC73935 CBI1 formic CBI1 formic是一种共价BAX抑制剂。
  49. GC73932 WK369 WK369是一种新型的BCL6小分子抑制剂,具有良好的抗卵巢癌生物活性,可诱导细胞周期阻滞和细胞凋亡。
  50. GC73928 BDM19 BDM19并单独或与BCL-2/BCL-XL抑制剂Navitoclax联合诱导细胞凋亡。
  51. GC73925 YSR734 YSR734(化合物21)是一种共价HDAC抑制剂,对HDAC1、HDAC2和HDAC3的IC50值分别为110 nM、154 nM和143 nM。

Items 51 to 100 of 2733 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction